Medicinal plants in history
Health workforce shortages. Lengthening waiting lists. Hospital cost over-runs. Type 2 Diabetes, the hidden epidemic. Pandemic viruses. Antibiotic resistance. Aging populations. Increasing meth use. There’s certainly more than a few nightmares for health policy analysts and decision makers to grapple with, when determining how to best allocate government health spending.
Apart from needing food and shelter, being able to resist the many life-threatening and injurious events and diseases that living on Planet Earth entails, has always been essential for our survival as a species. Thus in addition to having food security (access to sufficient healthy and nutritious food), the adequate supply of affordable and efficacious medicines, is a fundamental requirement to ensure good health and survival of human populations.
Humans have traditionally relied largely upon plants and fungi for medicines, and history shows they have served us well. However, despite the development of chemical drugs occurring only just over a hundred years ago, we often fail to acknowledge how the supply chain of medicinal plants, has greatly influenced the course of human history to date.
During the second world war, Cinchona officinalis (Peruvian bark) for instance, from which the valuable antimalarial drug quinine derives, was sourced almost exclusively from Java in Indonesia. However, after the Japanese invasion in 1942 and the capture by Nazis of processing facilities in the Netherlands, allied forces experienced a critical shortage of antimalarial drugs, which subsequently limited their operations in the southwest Pacific. Concerted efforts were therefore made to establish Cinchona cultivation in other locations, and new plantations in south America were developed(1).
Trade in black pepper, cinnamon and many other spices from India, China and south east Asia to Europe, were key contributors to the accumulation of wealth in early ancient cities such as Constantinople, Alexandria, Damascus and Venice. Europeans fought the Crusades in large part to maintain a portal to the valuable spice trade. The Opium Wars between China, Britain and France in the mid 19th century, arose from China’s attempts to suppress the large European controlled trade of opium to China at that time.
These and many other examples, are reminders about how plants with powerful pharmacological properties have been important to humans. And how our access to them through either trade barriers and/or insufficient local production, can become seriously restricted.
Pandemic lessons
A key realisation that emerged early during the Covid-19 pandemic, was that despite years of well-funded research and development, drugs don’t provide all the answers when treating or preventing disease. A vaccine was developed and distribution commenced in near record time, but this still took many months and had many limitations. Distribution was delayed particularly to poorer countries, and a large percentage of the world’s population resorted as they always have done, to traditional plant medicines instead.
The pandemic also exposed the failure and cluster risks of modern global medicine supply chains. As levels of demand surged, enormous pressures were placed on already stretched supply chains, and widespread supply bottlenecks appeared. During the Covid-19 lockdown in February 2022, pharmacy and supermarket shelves in Aotearoa NZ were virtually cleared of analgesics as people stockpiled. China’s zero-Covid policy during the pandemic prompted the closures of its many production facilities. India, which obtains most of its active pharmaceutical ingredients (API’s) from China, feared an imminent shortage of these critical raw materials, and thus promptly halted its exports of many medicinal products.
Since the pandemic, shortages have occurred in supplies of widely used drugs such as the antidepressant fluoxetine, oestradiol patches used for menopause, and paracetamol. Similar shortfalls have happened in many other countries. The forthcoming withdrawal of the U.S. from the World Health Organisation, also doesn’t bode well for future international collaboration or worldwide medicine security.
Antibiotic resistance, is another ticking timebomb already responsible for over a million deaths a year globally, and placing a growing burden on health budgets. Rates of antimicrobial resistance are increasing in Aotearoa New Zealand and globally, including to last-line carbapenem antibiotics usually reserved for severe infections(2). It is a serious problem directly related to their overusage. Resistance to commonly used disinfectants and sanitizing agents, is also of increasing concern(3-5). Reducing their usage through increased utilization of plant derived medicines to help control infection, is a highly recommendable and evidence-based strategy.
Medicine shortfalls
Economic pressures, subsidisation policies and looser regulatory provisions in low-wage countries, have led to vital parts of medicine manufacturing being relocated to Asian countries over the past couple of decades. Historically also, global supplies of medicinal plants have largely derived from countries with low labour costs.
Most of the world’s pharmaceutical production, and around 30% of the production of plants for medicines, now takes place in China and India. The high concentration of drug manufacturing steps in a small number of sites, often concentrated in the same geographical area, makes a supply chain vulnerable(6). Modern supply chain concepts such as just-in-time delivery, mean fewer reserves are maintained throughout the value chain.
The rapidly increasing frequency of so-called extreme weather events, reduced biodiversity, global warming and climate change, will also cause further threats to trade and supply chain security. These and other human factors are having increasingly serious impacts not only on food production and supplies, but also on the health and habitats of medicinal plants, and our ability to access them.
Geopolitical events, including wars or the introduction of trade tariffs, can also impact suddenly and significantly on our ability to access medicines which are manufactured or sourced from far away. With an increasingly unsettled international situation and tensions currently in a number of areas of the world, supply chain risks and strategies to mitigate these, should be high on a government’s agenda.
Medicine supplies – a government priority
Governments around the world have been considering and implementing additional measures to better secure medicine supply for their populations in the future. For a multitude of reasons, the inclusion of phytomedicines and their raw materials in these programmes, is essential.
Much was learned about the phytochemistry and potential medicinal properties of plants native to Aotearoa New Zealand during world war 2, when the government funded research in anticipation of a Japanese naval blockade limiting our imported medicine supply chain.
Cuba shifted to a more traditional and plant medicine based healthcare system following the introduction of a U.S. embargo in 1961. It now has some of the best health outcomes in the world, and its population’s average life expectancy is the same as that in the U.S. This has been achieved through an emphasis on prevention and education, universal coverage and access to treatment, within a highly proactive and well resourced primary healthcare system. Cuba’s spending per capita on health, is only a fraction of that allocated in the U.S., and less than half that spent in Aotearoa New Zealand (7).
Need for a Natural Health Agency
Healthy plant based foods and efficacious phytomedicines are powerful tools when building resilience to geopolitical or natural events which disrupt medicine supplies, and contribute greatly to better medicine security.
Aotearoa New Zealand is one of the best food and beverage producing countries in the world, with an ability to grow a wide range of foods and medicinal plants. From blueberries to kiwifruit, green tea to ginkgo, ginseng to saffron, numerous plants seem to have special characteristics and world leading levels of active phytochemicals, when grown here.
This capability together with a hard working and adaptable farming community, smart scientists and an innovative culture, provides the key criteria needed to further establish and promote a robust and export driven natural health product industry here. This could become a major contributor to our economy, as a sustainable, value added and profitable industry well aligned with our intrinsic and unique strengths as a country, and employ and retain both highly skilled and less skilled workforces. A scaled up commercial medicinal plant cultivation and processing industry would also help to mitigate risks from being over dependent on dairy and meat exports, and enable more self-sufficiency and medicine security, at the same time.
A New Zealand Space Agency was established in 2016, to be the lead government agency for space policy, regulation and sector development. This supports the ventures of companies such as Rocket Lab and Elon Musk’s SpaceX, and a NZ Space and Advanced Aviation Strategy 2024 to 2030 sets out the steps being taken to catalyse the sector’s growth.
In its current efforts to improve economic and wellbeing outcomes for Aotearoa New Zealand, it would be refreshing to see the government also implement the establishment of a Natural Health Agency. This could develop much needed new regulations for the sector, facilitate more research and development to support its growth, and improve patient access to evidence-based plant medicine treatments within primary health care. Expenditure on imported drug medicines would be reduced, and rural communities and our environment benefit through establishing new medicinal plant crops and related processing ventures.
The natural health products sector is a complex but highly promising one for Aotearoa New Zealand, and a strategic, well integrated and coordinated bipartisan programme resourced over several years and insulated from our three year election cycles, would be an excellent use of limited government funds, in these changing times.
And it should lead to more resilience and medicine security, when the next pandemic or serious geopolitical event pulls the carpet out from our currently largely imported medicine supply chain.
References:
- Shanks GD. Historical Review: Problematic Malaria Prophylaxis with Quinine. Am J Trop Med Hyg. 2016 Aug 3;95(2):269-72. doi: 10.4269/ajtmh.16-0138.
- Ministry of Health , Manatū Hauora. Growing risk of antimicrobial resistance infection in New Zealand, 18 Nov 2024. https://www.health.govt.nz/news/growing-risk-of-antimicrobial-resistance-infection-in-new-zealand#:~:text=’Resistant%20strains%20of%20bacteria%20and
- Van den Poel B, Saegeman V, Schuermans A. Increasing usage of chlorhexidine in health care settings: blessing or curse? A narrative review of the risk of chlorhexidine resistance and the implications for infection prevention and control. Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):349-362.
- Kampf G. Acquired resistance to chlorhexidine – is it time to establish an ‘antiseptic stewardship’ initiative? J Hosp Infect. 2016 Nov;94(3):213-227.
- Fernandes ÂR, Rodrigues AG, Cobrado L. Effect of prolonged exposure to disinfectants in the antimicrobial resistance profile of relevant micro-organisms: a systematic review. J Hosp Infect. 2024 Sep;151:45-59.
- OECD Health Policy Studies. Securing Medical Supply Chains in a Post-Pandemic World. OECD Health Policy Studies, OECD Publishing, Paris. ISSN 2024-319X (online)
- M, Sarvestani MA. A Review on the Approach to Herbal Medicine in Cuban Healthcare System. Hispanic Health Care International. 2024;0(0). doi:10.1177/15404153241291747
- https://herbblurb.com/2019/06/21/why-new-zealand-grown-herbs-are-best/

Cinchona seedlings growing in Washington DC, USA, in November 1943 taken from Mindanao in the Philippines to re-establish quinine production in the Americas.
US Army Photograph, now in the public domain.

